In this review of the latest biomarker data trends and challenges, you will discover how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can:
Move beyond data overload and leverage cutting-edge technologies to seamlessly transform millions of data points into actionable insights
Harness advanced informatics and visualization tools to harmonize disparate sources of biomarker data and warehouse them for effective on-study use), as well as downstream use
Build flexibility, efficiency, and compliance into the rapidly evolving biomarker-informed development process
Accelerate go/no-go decision-making to reduce time and cost